Blair William & Co. IL Purchases New Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Blair William & Co. IL acquired a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,000 shares of the company’s stock, valued at approximately $81,000.

Several other large investors also recently added to or reduced their stakes in the stock. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in shares of Recursion Pharmaceuticals by 143.4% during the 4th quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 200,470 shares of the company’s stock valued at $1,355,000 after acquiring an additional 118,118 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Recursion Pharmaceuticals by 38.8% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,277 shares of the company’s stock worth $191,000 after purchasing an additional 7,902 shares during the period. Vanguard Group Inc. boosted its holdings in Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock valued at $229,908,000 after purchasing an additional 9,737,196 shares during the last quarter. LPL Financial LLC grew its stake in shares of Recursion Pharmaceuticals by 2.0% in the 4th quarter. LPL Financial LLC now owns 367,785 shares of the company’s stock valued at $2,486,000 after buying an additional 7,347 shares during the period. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $210,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Trading Down 11.9 %

Shares of NASDAQ RXRX opened at $4.24 on Monday. The stock has a fifty day simple moving average of $7.22 and a 200-day simple moving average of $6.95. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.06 and a twelve month high of $12.36. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.70 billion, a PE ratio of -2.77 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business’s revenue was down 57.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.42) earnings per share. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on RXRX. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Leerink Partners cut their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. Finally, KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.